Ismael, S. (2026). Computational Exploration and Optimization of 6-Aryl-5-Cyano Thiouracil Scaffolds as Type-II VEGFR-2 Tyrosine Kinase Inhibitors: Insights from Docking, Molecular Dynamics, DFT, and ADMET Studies. , 23(3), 116-129. doi: 10.33899/iraqij.p.2026.171903.1212
Sarah Sedqi Ismael. "Computational Exploration and Optimization of 6-Aryl-5-Cyano Thiouracil Scaffolds as Type-II VEGFR-2 Tyrosine Kinase Inhibitors: Insights from Docking, Molecular Dynamics, DFT, and ADMET Studies". , 23, 3, 2026, 116-129. doi: 10.33899/iraqij.p.2026.171903.1212
Ismael, S. (2026). 'Computational Exploration and Optimization of 6-Aryl-5-Cyano Thiouracil Scaffolds as Type-II VEGFR-2 Tyrosine Kinase Inhibitors: Insights from Docking, Molecular Dynamics, DFT, and ADMET Studies', , 23(3), pp. 116-129. doi: 10.33899/iraqij.p.2026.171903.1212
Ismael, S. Computational Exploration and Optimization of 6-Aryl-5-Cyano Thiouracil Scaffolds as Type-II VEGFR-2 Tyrosine Kinase Inhibitors: Insights from Docking, Molecular Dynamics, DFT, and ADMET Studies. , 2026; 23(3): 116-129. doi: 10.33899/iraqij.p.2026.171903.1212

Computational Exploration and Optimization of 6-Aryl-5-Cyano Thiouracil Scaffolds as Type-II VEGFR-2 Tyrosine Kinase Inhibitors: Insights from Docking, Molecular Dynamics, DFT, and ADMET Studies

Iraqi Journal of Pharmacy
Article 4, Volume 23, Issue 3, September 2026, Pages 116-129    PDF (2.04 M)
Document Type: Research Paper
DOI: 10.33899/iraqij.p.2026.171903.1212
Author
Sarah Sedqi Ismael*
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq
Abstract
Background: This study presents the rationale for the in silico design and computational assessment of a novel set of six aryl 5-cyanothiouracil-based vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors as prospective anticancer agents. The compounds strategically integrate a hinge-binding pyrimidine core, a piperazine linker for alignment with the aspartate-phenylalanine-glycine (DFG) motif, and an oxadiazole–amide pharmacophore to mimic sorafenib’s critical hydrogen bonding within the adenosine triphosphate (ATP) pocket. Methods: Computational evaluation was conducted via molecular docking against VEGFR-2. The structural stability of the leading complex was validated through a 100 ns molecular dynamics (MD) simulation and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Density functional theory (DFT) evaluated electronic properties, while absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles were predicted. Results: Docking revealed multiple candidates achieving canonical type II binding modes with scores superior to sorafenib, maintaining essential contacts with Cys919, Glu885, and Asp1046. The MD simulation of the VEGFR-2/compound 10d complex confirmed high structural stability, minimal Root-Mean-Square Deviation (RMSD) fluctuations, and favorable MM-GBSA energies driven by lipophilic interactions. DFT calculations confirmed electronic suitability, with compound 10d showing the narrowest frontier orbital gaps. Predicted ADMET profiles indicated adequate oral absorption, though showing class-wide liabilities for cytochrome P450 (CYP), human Ether-à-go-go-Related Gene (hERG), and hepatotoxicity. Compound 10a displayed the most favorable pharmacokinetic profile. Conclusion: Compounds 10a and 10d were successfully identified as promising lead scaffolds targeting VEGFR-2, providing a robust computational foundation for further experimental validation and optimization.

Keywords
Angiogenesis; Anticancer agents; Molecular modelling; Pyrimidine; Sorafenib
Supplementary Files
References
  1. Eldehna WM, Habib YA, Mahmoud AE, Barghash MF, Elsayed ZM, Elsawi AE, et al. Design, synthesis, and in silico insights of novel N’-(2-oxoindolin-3-ylidene) piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors. Bioorganic chemistry 2024;153:107829.
  2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024;74(3):229-263. .
  3. Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer communications 2022;42(10):913-36.
  4. Wahab KA, Hassan A, Morsi A, Amritlal S, Meiwald A, Hughes R, Fox A, Bencina G, Pöllinger B. The indirect costs of five cancers in Egypt: years of life lost and productivity costs. Journal of Medical Economics 2025;28(1):36-43.
  5. Singh SR, Bhaskar R, Ghosh S, Yarlagadda B, Singh KK, Verma P, Sengupta S, Mladenov M, Hadzi-Petrushev N, Stojchevski R, Sinha JK, Avtanski D. Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes. Cancers (Basel) 2025;17(7):1082.
  6. Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World journal of clinical oncology 2011;2(2):80.
  7. Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discover oncology 2025;16(1):607.
  8. Shuel SL. Targeted cancer therapies: Clinical pearls for primary care. Canadian Family Physician 2022;68(7):515.
  9. Silnitsky S, Rubin SJS, Zerihun M, Qvit N. An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases. International Journal of Molecular Sciences 2023;24(24):17600.
  10. Taylor SS, Radzio-Andzelm E. Three protein kinase structures define a common motif. Structure 1994;2(5):345-55.
  11. Roskoski Jr R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological research 2016;103:26-48.
  12. Fu, Y., Nagy, J.A., Dvorak, A.M., Dvorak, H.F. (2008). Tumor Blood Vessels. In: Teicher, B.A., Ellis, L.M. (eds) Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-184-0_12
  13. Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, et al. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS chemical biology 2014;9(6):1230-41.
  14. Shehda MS, Almatary AM, Salem MS, Aboutaleb MH, Takizawa S, Aziz YM, El-Sayed MA, Elrayess R. Design and synthesis of sorafenib-inspired benzofuran hybrids as VEGFR-2 inhibitors: antiproliferative evaluation, mechanistic insights, and docking studies in hepatocellular carcinoma. RSC Medicinal Chemistry 2026;17(1):477-493.
  15. Thombre KR, Gupta KR, Umekar MJ. Design, Docking, ADMET, Pass, Synthesis and Bio-Evaluation of Novel 7-O-Substituted Chrysin-Based VEGFR-2 Inhibitors. Chemical Biology & Drug Design 2026;107(2):e70250.
  16. Abdelall EK, Elshemy HA, Abdelmegeed H, Ryad N, Abdelaziz AA. Novel quinoxaline derivatives as promising cytotoxic agents: structure-based design, in silico studies, VEGFR-2 inhibition, and PI3K/AKT/mTOR pathway modulation. Bioorganic Chemistry 2025;166:109116.
  17. Mahdy H, Elnagar H, Sakr H. recent advances on pyrimidine derivatives as anticancer agents. Al-Azhar Journal of Pharmaceutical Sciences 2023;67(1):51-67.
  18. Nadar S, Khan T. Pyrimidine: An elite heterocyclic leitmotif in drug discovery-synthesis and biological activity. Chemical Biology & Drug Design 2022;100(6):818-42.
  19. Chang E, Weinstock C, Zhang L, Fiero MH, Zhao M, Zahalka E, et al. FDA Approval summary: tivozanib for relapsed or refractory renal cell carcinoma. Clinical Cancer Research 2022;28(3):441-5.
  20. Al-Ghulikah HA, El-Sebaey SA, Bass AK, El-Zoghbi MS. New pyrimidine-5-carbonitriles as COX-2 inhibitors: design, synthesis, anticancer screening, molecular docking, and in silico ADME profile studies. Molecules 2022;27(21):7485.
  21. Osman IA, Ayyad RR, Mahdy HA. New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activities: design, molecular modeling and synthesis. New Journal of Chemistry 2022;46(24):11812-27.
  22. Eldehna WM, El Kerdawy AM, Al-Ansary GH, Al-Rashood ST, Ali MM, Mahmoud AE. Type IIA-Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. European Journal of Medicinal Chemistry 2019;163:37-53.
  23. Ragnarsson U, Fransson B, Grehn L. Experiments related to the synthesis and analysis of a hydrazine library. Journal of the Chemical Society, Perkin Transactions 1 2000;29(9):1405-9
  24. Khater I, Nassar A. Targeting EGFR and VEGFR-2 kinases with nanoparticles: a computational approach for cancer therapy advancement. Cancer Investigation 2024;42(2):176-85.
  25. Karatas H, Aydin M, Turkmenoglu B, Akkoc S, Sahin O, Kokbudak Z. Design, synthesis, cytotoxic activity, and in silico studies of new Schiff bases including pyrimidine core. ChemistrySelect 2023;8(6):e202204221.
  26. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009;30(16):2785-2791.
  27. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2010;31(2):455-461.
  28. Buccheri R, Rescifina A. High-Throughput, High-Quality: Benchmarking GNINA and AutoDock Vina for Precision Virtual Screening Workflow. Molecules 2025;30(16):3361.
  29. Bowers KJ, Chow DE, Xu H, Dror RO, Eastwood MP, Gregersen BA, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing (SC06). Tampa, FL: IEEE; 2006. p. 43-50. https://doi.org/10.1145/1188455.1188544
  30. Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron 2018;99(6):1129-1143.
  31. Asogwa FC, Ogechi EC, Louis H, Izuchukwu UD, Apebende CG, Florence EU, et al. Synthesis, characterization, DFT studies and molecular docking investigation of 2-oxo-ethyl piperidine pentanamide-derived sulfonamides as anti-diabetic agents. Results in Chemistry 2022;4:100672.
  32. Myung Y, de Sá AG, Ascher DB. Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic acids research 2024;52(W1):W469-W75.
  33. Dasmahapatra U, Kumar CK, Das S, Subramanian PT, Murali P, Isaac AE, Ramanathan K, Mm B, Chanda K. In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo [4, 5-c] quinolines as potential anti-tumor agents. Frontiers in chemistry 2022 Sep 30;10:991369.
  34. Kambe S, Saito K, Kishi H, Sakurai A, Midorikawa H. A one-step synthesis of 4-oxo-2-thioxopyrimidine derivatives by the ternary condensation of ethyl cyanoacetate, aldehydes, and thiourea. Synthesis 1979;1979(04):287-9.
  35. El-Dydamony NM, Abdelnaby RM, Abdelhady R, Ali O, Fahmy MI, R. Fakhr Eldeen R, et al. Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. Journal of Enzyme Inhibition and Medicinal Chemistry 2022;37(1):895-911.
  36. Hussain H, Green IR, Ahmed I. Journey describing applications of oxone in synthetic chemistry. Chemical reviews 2013;113(5):3329-71.
  37. Nasser AA, Eissa IH, Oun MR, El-Zahabi MA, Taghour MS, Belal A, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Organic and biomolecular chemistry 2020;18(38):7608-34.
  38. Thanikachalam PV, Maurya RK, Garg V, Monga V. An insight into the medicinal perspective of synthetic analogs of indole: A review. European journal of medicinal chemistry 2019;180:562-612.
  39. Parves MR, Riza YM, Alam S, Jaman S. Molecular dynamics-based insight of VEGFR-2 kinase domain: a combined study of pharmacophore modeling and molecular docking and dynamics. Journal of Molecular Modeling 2023;29(1):17.
  40. Sharma N, Bhati A, Shah K, Dewangan HK. Combating Sorafenib Resistance in Hepatocellular Carcinoma: Unlocking Potential with Combination Therapies and Structure-Activity Relationship Studies. Anti-Cancer Agents in Medicinal Chemistry. http://dx.doi.org/10.2174/0118715206388518251227044948
  41. Abdel-Mohsen HT, Ibrahim MA, Nageeb AM, El Kerdawy AM. Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors. BMC chemistry 2024;18(1):42.
  42. Modi SJ, Kulkarni VM. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II,‘DFG-out’inhibitors. Journal of Biomolecular Structure and Dynamics 2022;40(12):5712-27.
  43. Zhao Y, Lu H. A comprehensive description of VEGF-R1/2 small molecule inhibitors as anticancer agents. Bioorganic Chemistry 2025;166:109159.
  44. Backes AC, Zech B, Felber B, Klebl B, Müller G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert opinion on drug discovery 2008;3(12):1427-49.
  45. Hagras M, Saleh MA, Ezz Eldin RR, Abuelkhir AA, Khidr EG, El-Husseiny AA, El-Mahdy HA, Elkaeed EB, Eissa IH. 1, 3, 4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. Journal of enzyme inhibition and medicinal chemistry 2022;37(1):386-402.
  46. Gu X, Li L, Yin J, Zuo Z. Discovery of novel VEGFR-2 inhibitors through virtual screening, synthesis and bioactivity evaluation. Bioorganic and Medicinal Chemistry Letters 2025:130423. https://doi.org/10.1016/j.bmcl.2025.130423
  47. Ivanova L, Tammiku-Taul J, García-Sosa AT, Sidorova Y, Saarma M, Karelson M. Molecular dynamics simulations of the interactions between glial cell line-derived neurotrophic factor family receptor GFRα1 and small-molecule ligands. ACS omega 2018;3(9):11407-14.
  48. Asogwa FC, Ogechi EC, Louis H, Izuchukwu UD, Apebende CG, Florence EU, et al. Synthesis, characterization, DFT studies and molecular docking investigation of 2-oxo-ethyl piperidine pentanamide-derived sulfonamides as anti-diabetic agents. Results in Chemistry 2022;4:100672.
  49. Myung Y, de Sá AG, Ascher DB. Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic acids research 2024;52(W1):W469-W75.
Statistics
Article View: 327
PDF Download: 245


Journal Management System. Powered by iJournalPro.com